[
    "{\"step_by_step_thinking\": \"Document 0 suggests that a longer treatment duration was identified as an adverse factor in low-risk patients. Document 1 also supports this by stating that prolonging treatment duration has an adverse effect in low-risk patients with prostate cancer. Document 2, however, states that overall treatment time did not significantly influence any of the outcome endpoints. Document 20 suggests that prolonged treatment delays and missing three or more EBRT treatments was associated with poorer OS in patients with high-risk adenocarcinoma of the prostate. Document 27 suggests that patients treated with radiation therapy for stage T2 localized prostate carcinoma showed a greater incidence of pelvic and chemical failures and a lower cause-specific survival when elapsed treatment time was > 9 weeks in comparison with the failure and survival rates occurring with shorter times. Document 30 suggests that a 2.0% [95% CI 1.1-3.2] improvement in RFS is achieved for each Gy, suggesting a dose-response relationship. Document 31 suggests that the overall treatment time does not have an impact on the outcome of definitive radiotherapy for localized prostate carcinoma. Therefore, the evidence seems to suggest that treatment duration can affect the outcome after radiotherapy for prostate cancer, but it may depend on the risk level of the patient and other factors.\", \"answer_choice\": \"A\"}"
]